Kercheville Advisors, LLC Tyme Technologies, Inc. Transaction History

Kercheville Advisors, LLC

$236 Million
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Jul 18, 2022	SELL	$0.23 - $0.35 $9,200 - $14,000	-40,000 Reduced 38.83%	63,020 $18,000
Q1 2022 Apr 29, 2022	SELL	$0.28 - $0.68 $47,040 - $114,240	-168,000 Reduced 61.99%	103,020 $36,000
Q4 2021 Jan 26, 2022	SELL	$0.6 - $1.04 $254,070 - $440,388	-423,450 Reduced 60.97%	271,020 $163,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $119,395 - $166,430	-120,602 Reduced 14.8%	694,470 $715,000
Q2 2021 Nov 15, 2021	BUY	$1.14 - $1.87 $298,108 - $489,003	261,499 Added 47.24%	815,072 $1.03 Million
Q1 2021 Nov 15, 2021	BUY	$1.34 - $3.53 $311,552 - $820,732	232,502 Added 72.41%	553,573 $999,000
Q4 2020 Nov 12, 2021	BUY	$0.87 - $1.26 $279,331 - $404,549	321,071 New	321,071 $386,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kercheville Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kercheville Advisors, LLC with notifications on news.